

Nathan T Connell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9144489/publications.pdf>

Version: 2024-02-01

73
papers

1,246
citations

516710

16
h-index

395702

33
g-index

73
all docs

73
docs citations

73
times ranked

1551
citing authors

#	ARTICLE	IF	CITATIONS
1	Burnout in US hematologists and oncologists: impact of compensation models and advanced practice provider support. <i>Blood Advances</i> , 2023, 7, 3058-3068.	5.2	3
2	Gynecologic and obstetric management of women with von Willebrand disease: summary of 3 systematic reviews of the literature. <i>Blood Advances</i> , 2022, 6, 228-237.	5.2	15
3	von Willebrand factor levels in the diagnosis of von Willebrand disease: a systematic review and meta-analysis. <i>Blood Advances</i> , 2022, 6, 62-71.	5.2	17
4	To aPTT or not to aPTT: Evaluating the optimal monitoring strategy for unfractionated heparin. <i>Thrombosis Research</i> , 2022, 218, 199-200.	1.7	3
5	Surgical management of patients with von Willebrand disease: summary of 2 systematic reviews of the literature. <i>Blood Advances</i> , 2022, 6, 121-128.	5.2	7
6	Occam's Razor for Severe B12 Deficiency. <i>American Journal of Medicine</i> , 2022, , .	1.5	2
7	Impact of Hematology Electronic Consultations on Utilization of Referrals and Patient Outcomes in an Integrated Health Care System. <i>JCO Oncology Practice</i> , 2022, 18, e564-e573.	2.9	5
8	Laboratory assays of VWF activity and use of desmopressin trials in the diagnosis of VWD: a systematic review and meta-analysis. <i>Blood Advances</i> , 2022, 6, 3735-3745.	5.2	3
9	von Willebrand disease (VWD) and BATs: How do they connect and why should I care?. <i>Haemophilia</i> , 2022, 28, .	2.1	2
10	Outcomes of long-term von Willebrand factor prophylaxis use in von Willebrand disease: A systematic literature review. <i>Haemophilia</i> , 2022, 28, 373-387.	2.1	5
11	Response to "The 2021 von Willebrand disease guidelines: Clarity and controversy". <i>Haemophilia</i> , 2022, 28, 371-372.	2.1	3
12	Tocilizumab for treatment of cutaneous and systemic manifestations of vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome without myelodysplastic syndrome. <i>JAAD Case Reports</i> , 2022, 23, 15-19.	0.8	33
13	Update on pregnancy-associated venous thromboembolism. <i>Thrombosis Update</i> , 2022, 8, 100107.	0.9	1
14	International survey on Helicobacter pylori testing in patients with immune thrombocytopenia: Communication of the platelet immunology scientific and standardization committee. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 287-296.	3.8	13
15	Clinical Significance of CBC and WBC Morphology in the Diagnosis and Clinical Course of COVID-19 Infection. <i>American Journal of Clinical Pathology</i> , 2021, 155, 364-375.	0.7	61
16	ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. <i>Blood Advances</i> , 2021, 5, 301-325.	5.2	152
17	Management of therapeutic unfractionated heparin in COVID-19 patients: A retrospective cohort study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12521.	2.3	3
18	Intermediate versus standard dose heparin prophylaxis in COVID-19 ICU patients: A propensity score-matched analysis. <i>Thrombosis Research</i> , 2021, 203, 57-60.	1.7	8

#	ARTICLE	IF	CITATIONS
19	Acquired von Willebrand Syndrome. Hematology/Oncology Clinics of North America, 2021, 35, 1103-1116.	2.2	12
20	Oxaliplatin hypersensitivity complicated by thrombocytopenia during desensitization. Annals of Allergy, Asthma and Immunology, 2021, 127, 267-269.	1.0	4
21	Use of Social Media in the Practice of Medicine. American Journal of Medicine, 2021, , .	1.5	2
22	Bleeding assessment tools in the diagnosis of VWD in adults and children: a systematic review and meta-analysis of test accuracy. Blood Advances, 2021, 5, 5023-5031.	5.2	6
23	ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Advances, 2021, 5, 280-300.	5.2	246
24	Inherited Bleeding Disorders. Hematology/Oncology Clinics of North America, 2021, 35, xiii-xiv.	2.2	0
25	Inherited Bleeding Disorders. Hematology/Oncology Clinics of North America, 2021, 35, i.	2.2	0
26	von Willebrand disease: proposing definitions for future research. Blood Advances, 2021, 5, 565-569.	5.2	5
27	Anticoagulation Use and Outcomes Among Patients with Atrial Fibrillation and Von Willebrand Disease. Blood, 2021, 138, 590-590.	1.4	0
28	Diversity, Equity, and Inclusion in Hematology and Oncology Fellowship Programs. Blood, 2021, 138, 2977-2977.	1.4	3
29	How to manage bleeding disorders in aging patients needing surgery. Hematology American Society of Hematology Education Program, 2021, 2021, 529-535.	2.5	2
30	An international survey to inform priorities for new guidelines on von Willebrand disease. Haemophilia, 2020, 26, 106-116.	2.1	32
31	Pregnancy outcomes, risk factors, and cell count trends in pregnant women with essential thrombocythemia. Leukemia Research, 2020, 98, 106459.	0.8	16
32	Venous thromboembolism in the hormonal milieu. Current Opinion in Hematology, 2020, 27, 327-332.	2.5	3
33	VTE in ICU Patients With COVID-19. Chest, 2020, 158, 2130-2135.	0.8	76
34	Systems-based hematology: highlighting successes and next steps. Blood Advances, 2020, 4, 4574-4583.	5.2	8
35	Coagulopathy of COVID-19 and antiphospholipid antibodies. Journal of Thrombosis and Haemostasis, 2020, 18, .	3.8	72
36	Taken the wrong way, a complement becomes catastrophic. Blood, 2020, 135, 233-234.	1.4	2

#	ARTICLE	IF	CITATIONS
37	Treatment of Acquired Hemophilia a with Rituximab and Emicizumab. <i>Blood</i> , 2020, 136, 18-19.	1.4	2
38	Cost-Effectiveness of Long-Term Prophylaxis Versus on-Demand Treatment with Von Willebrand Factor Concentrate in Severe Inherited Von Willebrand Disease. <i>Blood</i> , 2020, 136, 4-5.	1.4	1
39	Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071987472.	2.5	50
40	Cost-effectiveness of edoxaban versus dalteparin for the treatment of cancer-associated thrombosis. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 382-386.	2.1	7
41	Plasmacytoma presenting as jugular foramen tumor in a young woman with multiple myeloma. <i>American Journal of Hematology</i> , 2019, 94, 728-732.	4.1	2
42	Fostamatinib for the treatment of chronic immune thrombocytopenia. <i>Blood</i> , 2019, 133, 2027-2030.	1.4	64
43	Ravulizumab: a complementary option for PNH. <i>Blood</i> , 2019, 133, 503-504.	1.4	8
44	Associations between hematology/oncology fellowsâ€™ training and mentorship experiences and hematology-only career plans. <i>Blood Advances</i> , 2019, 3, 3278-3286.	5.2	17
45	Andexanet Alfa (Andexxa) Formulary Review. <i>Critical Pathways in Cardiology</i> , 2019, 18, 66-71.	0.5	17
46	Pregnancy Outcomes, Risk Factors, and Gestational Cell Count Trends in Pregnant Women with Essential Thrombocythemia and Polycythemia Vera. <i>Blood</i> , 2019, 134, 4172-4172.	1.4	6
47	Mentorship Experiences Among Second-Year U.S. Hematology/Oncology Fellows in the 2019 ASH Hematology/Oncology Fellows Survey. <i>Blood</i> , 2019, 134, 2124-2124.	1.4	1
48	Prechemotherapy Education: Reducing Patient Anxiety Through Nurse-Led Teaching Sessions. <i>Clinical Journal of Oncology Nursing</i> , 2018, 22, 76-82.	0.6	15
49	Imatinib-induced drug reaction with eosinophilia and systemic symptoms in solid tumors. <i>Anti-Cancer Drugs</i> , 2018, 29, 919-923.	1.4	7
50	The Spleen and Its Disorders. , 2018, , 2313-2327.		3
51	Implementation of a Venous Thromboembolism Prophylaxis Protocol Using the Caprini Risk Assessment Model in Patients Undergoing Mastectomy. <i>Annals of Surgical Oncology</i> , 2018, 25, 3548-3555.	1.5	17
52	Oxaliplatin Induced Immune Thrombocytopenia in Patients with Oxaliplatin Hypersensitivity: Implications for Desensitization. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, AB41.	2.9	2
53	Low-molecular weight heparin versus vitamin K antagonists for the treatment of cancer-associated thrombosis: A cost-effectiveness analysis. <i>Thrombosis Research</i> , 2017, 150, 53-58.	1.7	9
54	Pregnancy outcomes in inherited bone marrow failure syndromes. <i>Blood</i> , 2017, 130, 1671-1674.	1.4	12

#	ARTICLE	IF	CITATIONS
55	Factoring in the missing link. American Journal of Hematology, 2017, 92, 110-113.	4.1	0
56	HIT the price point with fondaparinux. Blood, 2016, 128, 3019-3020.	1.4	0
57	Which â€™roid is all the rage?. Blood, 2016, 127, 273-273.	1.4	0
58	Management of Dabigatranâ€™Associated Bleeding with Two Doses of Idarucizumab Plus Hemodialysis. Pharmacotherapy, 2016, 36, e160-e165.	2.6	35
59	Transfusion Medicine. Primary Care - Clinics in Office Practice, 2016, 43, 651-659.	1.6	19
60	Effect of ADAMTS13 activity turnaround time on plasma utilization for suspected thrombotic thrombocytopenic purpura. Transfusion, 2016, 56, 354-359.	1.6	37
61	The role of hematologists in a changing United States health care system. Blood, 2015, 125, 2467-2470.	1.4	15
62	Cost-Effectiveness Analysis of Warfarin Versus Low-Molecular Weight Heparin for the Treatment of Malignancy-Associated Venous Thromboembolism. Blood, 2015, 126, 746-746.	1.4	9
63	Attending Physician Attitudes Toward Choice of Oral Anticoagulant for the Treatment of Venous Thromboembolism. Rhode Island Medical Journal (2013), 2015, 98, 32-6.	0.2	2
64	Correlation Of ADAMTS13 Activity With Baseline Characteristics and Management Patterns In Patients With Suspected Thrombotic Thrombocytopenic Purpura In The State Of Rhode Island. Blood, 2013, 122, 3556-3556.	1.4	0
65	Does My Patient Have a Life- or Limb-Threatening Thrombocytopenia?. Hematology/Oncology Clinics of North America, 2012, 26, 369-382.	2.2	2
66	Assessment of the effectiveness of a prechemotherapy teaching session: A Brown University Oncology Group study.. Journal of Clinical Oncology, 2012, 30, 260-260.	1.6	2
67	Splenosis and sepsis: The born-again spleen provides poor protection. Virulence, 2011, 2, 4-11.	4.4	34
68	Splenic cyst manifesting as gastric outlet obstruction. Medicine and Health, Rhode Island, 2011, 94, 218.	0.1	0
69	Oseltamivir-resistant 2009â€™2010 pandemic influenza A (H1N1) in an immunocompromised patient. Clinical Microbiology and Infection, 2010, 16, 1576-1578.	6.0	22
70	Alphabet soup: RAEB, HMA, DOE, and AFOP. Medicine and Health, Rhode Island, 2010, 93, 385-6.	0.1	1
71	<i>Klebsiella pneumoniae</i> endophthalmitis with associated hepatic abscess. Journal of Hospital Medicine, 2007, 2, 442-444.	1.4	3
72	Sideroblastic Anemias. , 0, , 44-47.		0

#	ARTICLE	IF	CITATIONS
73	Human Immunodeficiency Virus-Associated Malignancies. , 0, , 169-183.		0